Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis
A prospective cohort study
- Stephen M.P. O'Riordan, MRCPI, MD1,2,3,4,
- Peter Hindmarsh, MD, FRCPCH4,
- Nathan R. Hill, DPHIL, MBCS5,6,
- David R. Matthews, DPHIL, FRCP5,6,
- Sherly George, MSC1,
- Peter Greally, MD, FRCPI1,
- Gerard Canny, MD, FRCPI2,
- Dubhfeasa Slattery, PHD, FRCPI3,
- Nuala Murphy, MD, FRCPI3,
- Edna Roche, MD, FRCPI1,7,
- Colm Costigan, FRCPI2 and
- Hilary Hoey, MD, FRCPI1,7
- 1National Children's Hospital, Tallaght, Dublin, Ireland;
- 2Our Lady's Children's Hospital, Crumlin, Dublin, Ireland;
- 3Children's University Hospital, Temple Street, Dublin, Ireland;
- 4Institute of Child Health, University College London, Developmental Endocrinology Research Group, London, U.K.;
- 5Oxford Centre for Diabetes Endocrinology and Diabetes (OCDEM), Oxford, U.K.;
- 6National Institute of Health Research (NIHR), Oxford Biomedical Research Centre, Oxford, U.K.;
- 7University of Dublin, Trinity College, Dublin, Ireland.
- Corresponding author: Stephen O'Riordan, s.oriordan{at}ich.ucl.ac.uk.
Abstract
OBJECTIVE To validate continuous glucose monitoring (CGM) in children and adolescents with cystic fibrosis.
RESEARCH DESIGN AND METHODS Paired oral glucose tolerance tests (OGTTs) and CGM monitoring was undertaken in 102 children and adolescents with cystic fibrosis (age 9.5–19.0 years) at baseline (CGM1) and after 12 months (CGM2). CGM validity was assessed by reliability, reproducibility, and repeatability.
RESULTS CGM was reliable with a Bland-Altman agreement between CGM and OGTT of 0.81 mmol/l (95% CI for bias ± 2.90 mmol/l) and good correlation between the two (r = 0.74–0.9; P < 0.01). CGM was reproducible with no significant differences in the coefficient of variation of the CGM assessment between visits and repeatable with a mean difference between CGM1 and CGM2 of 0.09 mmol/l (95% CI for difference ± 0.46 mmol/l) and a discriminant ratio of 13.0 and 15.1, respectively.
CONCLUSIONS In this cohort of children and adolescents with cystic fibrosis, CGM performed on two occasions over a 12-month period was reliable, reproducible, and repeatable.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received October 24, 2008.
- Accepted March 3, 2009.
-
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
- © 2009 by the American Diabetes Association.
